Immunometabolic targeting of NK cells to solid tumors

Abstract The function of natural killer cells in tumors is often impaired due to metabolic adaptations of cancer cells, which causes reprogramming of natural killer cell effector and metabolic functions in favor of impaired immunity. As a result, targeting natural killer cells to solid tumors grapples with cells that meet a hostile environment unable to support effector functions. This not only results in cancers that are able to evade targeting, but also promotes natural killer cell dysfunction, most commonly manifested through altered phenotypic and functional signatures. In this chapter, we review the key elements driving natural killer cell metabolism, highlight the role of metabolism in supporting their function against solid tumors, and discuss targeting strategies to drive natural killer cells to solid tumors for immunotherapy.

• Publication year

  2021

• Venue

  Successes and Challenges of NK Immunotherapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/b978-0-12-824375-6.00015-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells.

  2020cited by this paper
• Functional and metabolic targeting of natural killer cells to solid tumors

  2020cited by this paper
• NK cell infiltration is associated with improved overall survival in solid cancers: A systematic review and meta-analysis

  2020cited by this paper
• Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways

  2020cited by this paper
• CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma

  2020cited by this paper
• CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

  2020cited by this paper
• 21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery

  2019cited by this paper
• The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy.

  2019cited by this paper
• Immunometabolic Responses of Natural Killer Cells to Inhibitory Tumor Microenvironment Checkpoints

  2019cited by this paper
• Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma

  2019cited by this paper
• Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma

  2019cited by this paper
• Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy

  2019cited by this paper
• NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

  2019cited by this paper
• Amendment history : Expression of Concern ( July 2019 ) Tandem CAR T cells targeting HER 2 and IL 13 R a 2 mitigate tumor antigen escape

  2019cited by this paper
• Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors

  2019cited by this paper
• A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

  2018cited by this paper
• Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells

  2018cited by this paper
• A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

  2018cited by this paper
• Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E

  2018cited by this paper
• Abstract 4743: Inhibition of theHif1a-mediated checkpoint refuels NK activation in cancer

  2018cited by this paper
• The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy

  2018cited by this paper
• Lactate-Mediated Acidification of Tumor Microenvironment Induces Apoptosis of Liver-Resident NK Cells in Colorectal Liver Metastasis

  2018cited by this paper
• Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

  2018cited by this paper
• Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

  2018cited by this paper
• Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

  2018cited by this paper
• Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration

  2018cited by this paper
• Coming of Age: CD96 Emerges as Modulator of Immune Responses

  2018cited by this paper
• Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation

  2018cited by this paper
• KIR downregulation by IL‐12/15/18 unleashes human NK cells from KIR/HLA‐I inhibition and enhances killing of tumor cells

  2018cited by this paper
• Tumor Antigen Escape from CAR T-cell Therapy.

  2018cited by this paper
• NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

  2018cited by this paper
• The hypoxic tumour microenvironment

  2018cited by this paper
• TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

  2018cited by this paper
• A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.

  2018cited by this paper
• Adenosinergic Signaling Alters Natural Killer Cell Functional Responses

  2018cited by this paper
• Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN‐γ and induces NK cell‐dependent lymphoma control without other immunotherapies

  2017cited by this paper
• TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

  2017cited by this paper
• Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis

  2017cited by this paper
• Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

  2017cited by this paper
• Targeting NK-cell checkpoints for cancer immunotherapy.

  2017cited by this paper
• The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

  2017cited by this paper
• The Role of Activating and Inhibitory NK Cell Receptors in Antitumor Immune Response

  2017cited by this paper
• Srebp-controlled glucose metabolism is essential for NK cell functional responses

  2017cited by this paper
• Role of NOX2-Derived Reactive Oxygen Species in NK Cell–Mediated Control of Murine Melanoma Metastasis

  2017cited by this paper
• Short Term Hypoxia Synergizes with Interleukin 15 Priming in Driving Glycolytic Gene Transcription and Supports Human Natural Killer Cell Activities*

  2016cited by this paper
• KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer

  2016cited by this paper
• Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma

  2016cited by this paper
• PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma

  2016cited by this paper
• Toxicity and management in CAR T-cell therapy

  2016cited by this paper
• Murine Butyrophilin-Like 1 and Btnl6 Form Heteromeric Complexes in Small Intestinal Epithelial Cells and Promote Proliferation of Local T Lymphocytes

  2016cited by this paper
• Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

  2016cited by this paper
• Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.

  2016cited by this paper
• TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells

  2016cited by this paper
• Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.

  2016cited by this paper
• T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

  2016cited by this paper
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

  2016cited by this paper
• LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

  2016cited by this paper
• PD-1 marks dysfunctional regulatory T cells in malignant gliomas.

  2016cited by this paper
• T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

  2016cited by this paper
• Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment

  2016cited by this paper
• Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.

  2016cited by this paper
• Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells

  2016cited by this paper
• Anti-CD73 in cancer immunotherapy: awakening new opportunities.

  2016cited by this paper
• Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases

  2016cited by this paper
• GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

  2016cited by this paper
• Enhanced NK cell adoptive antitumor effects against breast cancer in vitro via blockade of the transforming growth factor-β signaling pathway

  2015cited by this paper
• Regulation of innate immune cell function by mTOR

  2015cited by this paper
• PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer

  2015cited by this paper
• The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8⁺ T Cells in Response to a Lethal Poxvirus Infection.

  2015cited by this paper
• Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

  2015cited by this paper
• Big opportunities for small molecules in immuno-oncology

  2015cited by this paper
• Lactic dehydrogenase and cancer: an overview.

  2015cited by this paper
• Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas–FasL-Dependent AICD

  2015cited by this paper
• The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells

  2015cited by this paper
• Balancing natural killer cell activation through paired receptors

  2015cited by this paper
• TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals

  2015cited by this paper
• Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

  2015cited by this paper
• Activation-Specific Metabolic Requirements for NK Cell IFN-γ Production

  2015cited by this paper
• CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

  2015cited by this paper
• The metabolic checkpoint kinase mTOR is essential for interleukin-15 signaling during NK cell development and activation

  2014cited by this paper
• SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells

  2014cited by this paper
• CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells

  2014cited by this paper
• The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

  2014cited by this paper
• Inhibition of lactate dehydrogenase activity as an approach to cancer therapy.

  2014cited by this paper
• Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

  2014cited by this paper
• Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells

  2014cited by this paper
• CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

  2014cited by this paper
• The Critical Role of IL-15–PI3K–mTOR Pathway in Natural Killer Cell Effector Functions

  2014cited by this paper
• Reversal of natural killer cell exhaustion by TIM-3 blockade

  2014cited by this paper
• Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade

  2014cited by this paper
• Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.

  2014cited by this paper
• Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.

  2014cited by this paper
• Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells

  2013cited by this paper
• A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis

  2013cited by this paper
• Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

  2013cited by this paper
• Mouse TIGIT inhibits NK‐cell cytotoxicity upon interaction with PVR

  2013cited by this paper
• CD39 and CD73 in immunity and inflammation.

  2013cited by this paper
• Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells

  2013cited by this paper
• Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.

  2013cited by this paper
• Analysis of KIR gene frequencies and HLA class I genotypes in breast cancer and control group.

  2013cited by this paper

• No citing papers are available for this paper.